An investigation into variability in the therapeutic response to deferiprone in patients with thalassemia major

Keyphrases

• β-Thalassemia (β-thal) 100%
• Deferiprone 100%
• Therapeutic Response 100%
• Hepatic Iron Content 66%
• Iron Overload 33%
• Liver Tissue 33%
• Plasma Vitamin C 22%
• Regression Analysis 11%
• Transfusion Index 11%
• Vitamin C 11%
• Long-term Treatment 11%
• Iron Stores 11%
• Pharmacokinetic Profile 11%
• Apparent Volume of Distribution 11%
• Iron Chelator 11%
• Serum Ferritin 11%
• Orally Active 11%
• Active Iron 11%
• C Concentration 11%
• Body Iron 11%
• Induced Toxicity 11%
• Vitamin C Deficiency 11%
• Liver Iron Concentration 11%
• Vitamin C Status 11%

Pharmacology, Toxicology and Pharmaceutical Science

• Thalassemia Major 100%
• Deferiprone 100%
• Iron 100%
• Ascorbic Acid 25%
• Volume of Distribution 8%
• Ferritin 8%
• Iron Poisoning 8%
• Iron Chelating Agent 8%
• Biological Product 8%
• Ascorbic Acid Deficiency 8%
• Pharmacokinetics 8%

Biochemistry, Genetics and Molecular Biology

• Vitamin C 100%
• Dry Weight 75%
• Vitamin Blood Level 50%
• Pharmacokinetics 25%
• Iron Storage 25%
• Iron Poisoning 25%
• Iron Overload 25%
• Ferritin Blood Level 25%